$-0.04 EPS Expected for Amphastar Pharmaceuticals, Inc. (AMPH)

February 19, 2018 - By Henry Gaston

 $ 0.04 EPS Expected for Amphastar Pharmaceuticals, Inc. (AMPH)
Investors sentiment increased to 0.91 in Q3 2017. Its up 0.15, from 0.76 in 2017Q2. It increased, as 11 investors sold Amphastar Pharmaceuticals, Inc. shares while 32 reduced holdings. 10 funds opened positions while 29 raised stakes. 20.04 million shares or 0.68% less from 20.18 million shares in 2017Q2 were reported.
Massachusetts-based Boston Advsr Lc has invested 0.02% in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH). Sg Americas Secs has 16,385 shares. Principal Group accumulated 280,328 shares. Sei Invs, Pennsylvania-based fund reported 72,251 shares. Nationwide Fund Advsrs owns 48,466 shares for 0% of their portfolio. Arizona State Retirement has invested 0% of its portfolio in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH). Pnc Fincl Svcs Group Incorporated Incorporated holds 394 shares. Thrivent Fincl For Lutherans reported 21,860 shares. Bancshares Of America Corporation De holds 53,901 shares or 0% of its portfolio. Ny State Teachers Retirement System, New York-based fund reported 14,596 shares. Parkside Bancorporation Trust has 0% invested in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH). Pinebridge Investments Limited Partnership holds 0% or 4,414 shares in its portfolio. California State Teachers Retirement Sys stated it has 58,013 shares. Moreover, Credit Suisse Ag has 0% invested in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH). Great West Life Assurance Can has invested 0% in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH).

Analysts expect Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) to report $-0.04 EPS on March, 12.They anticipate $0.02 EPS change or 33.33 % from last quarter’s $-0.06 EPS. After having $0.07 EPS previously, Amphastar Pharmaceuticals, Inc.’s analysts see -157.14 % EPS growth. The stock decreased 1.31% or $0.25 during the last trading session, reaching $18.78. About 111,197 shares traded. Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) has risen 8.19% since February 19, 2017 and is uptrending. It has underperformed by 8.51% the S&P500.

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Ratings Coverage

Among 6 analysts covering Amphastar Pharmaceuticals (NASDAQ:AMPH), 4 have Buy rating, 0 Sell and 2 Hold. Therefore 67% are positive. Amphastar Pharmaceuticals had 26 analyst reports since August 10, 2015 according to SRatingsIntel. Wells Fargo initiated Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) on Friday, February 19 with “Outperform” rating. The firm has “Buy” rating by Jefferies given on Friday, August 11. As per Friday, October 20, the company rating was maintained by Piper Jaffray. The firm has “Buy” rating given on Wednesday, August 9 by Piper Jaffray. The rating was maintained by BMO Capital Markets on Friday, November 10 with “Market Perform”. The company was downgraded on Tuesday, March 14 by Raymond James. Jefferies maintained Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) rating on Thursday, November 9. Jefferies has “Buy” rating and $23.0 target. Needham maintained it with “Buy” rating and $18.0 target in Friday, September 15 report. The stock of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) has “Hold” rating given on Thursday, November 9 by Raymond James. As per Tuesday, January 19, the company rating was maintained by Jefferies.

Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and sale of generic and proprietary injectable, inhalation, and intranasal products. The company has market cap of $863.42 million. It operates in two divisions, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients. It currently has negative earnings. The company's product portfolio comprises enoxaparin, a low molecular weight heparin that is used as an anticoagulant for prevention and treatment of deep vein thrombosis; naloxone for treating opioid overdose; Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection for the dispersion and absorption of other injected drugs; and lidocaine jelly, a local anesthetic product for urological procedures.

More notable recent Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) news were published by: Seekingalpha.com which released: “Amphastar Pharmaceuticals’ (AMPH) Management on Q3 2017 Results – Earnings …” on November 08, 2017, also Globenewswire.com with their article: “Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended …” published on May 08, 2017, Law360.com published: “Amphastar Fights Momenta, Sandoz Bid To Duck Antitrust Suit” on May 05, 2017. More interesting news about Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) were released by: Globenewswire.com and their article: “Amphastar Announces the Receipt of a CRL for Intranasal Naloxone for the …” published on February 21, 2017 as well as Marketwatch.com‘s news article titled: “Amphastar Pharmaceuticals Inc.” with publication date: February 29, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.